These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 21515628)

  • 1. Therapeutic effect of tocilizumab on two patients with polymyositis.
    Narazaki M; Hagihara K; Shima Y; Ogata A; Kishimoto T; Tanaka T
    Rheumatology (Oxford); 2011 Jul; 50(7):1344-6. PubMed ID: 21515628
    [No Abstract]   [Full Text] [Related]  

  • 2. Long-term efficacy of alemtuzumab in polymyositis.
    Ruck T; Bittner S; Kuhlmann T; Wiendl H; Meuth SG
    Rheumatology (Oxford); 2015 Mar; 54(3):560-2. PubMed ID: 25552256
    [No Abstract]   [Full Text] [Related]  

  • 3. Retention of tocilizumab and anti-tumour necrosis factor drugs in the treatment of rheumatoid arthritis.
    Hishitani Y; Ogata A; Shima Y; Hirano T; Ebina K; Kunugiza Y; Shi K; Narazaki M; Hagihara K; Tomita T; Yoshikawa H; Tanaka T; Kumanogoh A
    Scand J Rheumatol; 2013; 42(4):253-9. PubMed ID: 23470089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tocilizumab-induced hypofibrinogenemia: A report of 7 cases.
    Martis N; Chirio D; Queyrel-Moranne V; Zenut MC; Rocher F; Fuzibet JG
    Joint Bone Spine; 2017 May; 84(3):369-370. PubMed ID: 27324602
    [No Abstract]   [Full Text] [Related]  

  • 5. Dose tailoring of anti-tumour necrosis factor-alpha therapy delivers useful clinical efficacy in Crohn disease patients experiencing loss of response.
    Ghaly S; Costello S; Beswick L; Pudipeddi A; Agarwal A; Sechi A; Antoniades S; Headon B; Connor S; Lawrance IC; Sparrow M; Walsh AJ; Andrews JM;
    Intern Med J; 2015 Feb; 45(2):170-7. PubMed ID: 25370691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adalimumab induction for Crohn's disease.
    Cottone M; Mocciaro F; Scimeca D
    Gastroenterology; 2006 May; 130(6):1929. PubMed ID: 16697762
    [No Abstract]   [Full Text] [Related]  

  • 7. Long-term efficacy and safety of itolizumab in patients with moderate-to-severe chronic plaque psoriasis: A double-blind, randomized-withdrawal, placebo-controlled study.
    Dogra S; D S K; Budamakuntla L; Srinivas CR; Khopkar U; Gupta S; Shetty N; Pratap DV; Gopal MG; Rao TN; Garg V; Sumathy TK; Saraswat A; Bhat R; Kura M; Pandey N; Shah R; Sai Krishna K; Padmaja D; Manmohan G; M S R; Barve A; Montero E
    J Am Acad Dermatol; 2015 Aug; 73(2):331-3.e1. PubMed ID: 26183983
    [No Abstract]   [Full Text] [Related]  

  • 8. Adalimumab in rheumatoid arthritis.
    Moreland L
    Curr Rheumatol Rep; 2004 Oct; 6(5):333-4. PubMed ID: 15355743
    [No Abstract]   [Full Text] [Related]  

  • 9. Omalizumab Treatment of Vernal Keratoconjunctivitis.
    Heffler E; Picardi G; Liuzzo MT; Pistorio MP; Crimi N
    JAMA Ophthalmol; 2016 Apr; 134(4):461-3. PubMed ID: 26795360
    [No Abstract]   [Full Text] [Related]  

  • 10. Alemtuzumab (Campath-1H) for treatment of refractory polymyositis.
    Thompson B; Corris P; Miller JA; Cooper RG; Halsey JP; Isaacs JD
    J Rheumatol; 2008 Oct; 35(10):2080-2. PubMed ID: 18843768
    [No Abstract]   [Full Text] [Related]  

  • 11. [Case report and discussion of a patient with polymyositis, fibrosing alveolitis and scleroderma-like involvement of the right hand].
    Wunderlin B; Knüsel O; Kummer H
    Z Rheumatol; 1996; 55(3):188-97. PubMed ID: 8768149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.
    Smolen JS; Beaulieu A; Rubbert-Roth A; Ramos-Remus C; Rovensky J; Alecock E; Woodworth T; Alten R;
    Lancet; 2008 Mar; 371(9617):987-97. PubMed ID: 18358926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exacerbation of cerebral radiation necrosis by bevacizumab.
    Jeyaretna DS; Curry WT; Batchelor TT; Stemmer-Rachamimov A; Plotkin SR
    J Clin Oncol; 2011 Mar; 29(7):e159-62. PubMed ID: 21149667
    [No Abstract]   [Full Text] [Related]  

  • 14. A study to evaluate the safety, tolerability, and efficacy of brodalumab in subjects with rheumatoid arthritis and an inadequate response to methotrexate.
    Pavelka K; Chon Y; Newmark R; Lin SL; Baumgartner S; Erondu N
    J Rheumatol; 2015 Jun; 42(6):912-9. PubMed ID: 25877498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A case report of a patient with refractory adult-onset Still's disease who was successfully treated with tocilizumab over 6 years.
    Nakahara H; Mima T; Yoshio-Hoshino N; Matsushita M; Hashimoto J; Nishimoto N
    Mod Rheumatol; 2009; 19(1):69-72. PubMed ID: 18762861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epstein-Barr virus-driven lymphoproliferative disorder post-CAMPATH-1H (alemtuzumab) in refractory polymyositis.
    Cooles FA; Jackson GH; Menon G; Isaacs JD
    Rheumatology (Oxford); 2011 Apr; 50(4):810-2. PubMed ID: 21208978
    [No Abstract]   [Full Text] [Related]  

  • 17. Reduction of biological agent dose in rheumatic diseases: descriptive analysis of 153 patients in clinical practice conditions.
    Inciarte-Mundo J; Hernández MV; Rosario V; Ruiz-Esquide V; Cabrera-Villalba S; Ramírez J; Cañete JD; Sanmartí R
    Reumatol Clin; 2014; 10(1):10-6. PubMed ID: 23876791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infliximab in a case of early adult-onset Still's disease.
    Olivieri I; de Stefano G; Padula A; La Gala A; de Stefano C
    Clin Rheumatol; 2003 Oct; 22(4-5):369-70. PubMed ID: 14579170
    [No Abstract]   [Full Text] [Related]  

  • 19. [Patient with eosinophilic polymyositis].
    de Kruijf EJ; Rothbarth J; van Duinen SG; de Meijer PH; Meinders AE
    Ned Tijdschr Geneeskd; 2000 Oct; 144(42):2019-23. PubMed ID: 11072522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Summaries for patients. Adalimumab for the treatment of hidradenitis suppurativa.
    Ann Intern Med; 2012 Dec; 157(12):I-50. PubMed ID: 23247950
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.